Anabolic drugs have been in medical use for many decades, but the introduction of synthetic drugs called Selective Androgen Receptor Modulators (SARMs) has greatly revolutionised this sector.
As the name indicates, these drugs are extremely selective in the nature of how they work. Essentially, they trigger certain reactions in very precise parts of the body, without many side effects that end up being more severe than acceptable.
Traditional hormone treatments using testosterone for example, resulted in reactions in many different organs including kidneys and prostate where it can cause more damage than good.
Different types of SARMs have been developed for treatment of many conditions including muscle wasting and osteoporosis. One of the positive side effects some of these trials have identified is more effective fat burning.
One such drug is Stenabolic SR9009 which has proven to be one of the most effective fat burners. The reason is that the physiological triggers result in a boosted metabolic rate that causes the liver to break down more blood sugar and fat.
What Affects Metabolic Rates?
Essentially it’s a combination of diet and exercise. But physically working hard is the main trigger that increases your metabolism as your body demands more energy. Your liver starts to increase the rate of sugar and fat breakdown which then releases energy.
The harder and longer you push your body through cardio exercises, the higher your metabolic rate will climb.
However, SARMS, and Stenabolic SR9009 in particular, help to trigger the physiological processes that increase the levels of the Rev-ErbA protein. And this directly affects how much fat your body will process, even in a complete resting state.
It’s the main reason that it has been called “Cardio in a Bottle”.
In order to shed some more light on this effect, we have looked at some of the most important research studies. The results of these are summarised here in an easy to understand non-scientific language.
What Studies Have Shown
Over the past 20 years, the development of SARMs has increased significantly. With many clinical and pre-clinical studies underway, one thing has become very evident. The selectiveness of the drugs provide highly tailored triggers to allow for very specific treatments with little or no side effects.
To help you understand what studies have shown so far, we want to provide some insights from research studies and clinical trials that have focused on the metabolic triggers of certain SARMs.
In the following studies you fill find some very promising results and indications of future research areas.
Study 1 Results
The first study we want to draw attention to is research performed by The Scripps Research Institute in Florida. The purpose of this research was to combine the results from multiple clinical studies to identify what the exact physiological impacts were.
There were two very specific areas of focus which were the metabolic impacts and influences on the body clock (circadian). The main drugs that were focused on were SR9009 and SR9011, which both resulted in very similar physiological processes being triggered.
The dugs in question are classified as REV-ERB agonists. This is a scientific way of describing the receptors in the body that trigger the production of certain proteins. With SARMs the proteins that are produced are extremely specific, and in this case they were related to body clock and metabolic functions.
By binding to the REV-ERB receptors, the body increases the release of proteins that boost the metabolic rate. This was measurable through an increased processing of glucose as well as a 5% increase in VO2, or oxygen consumption.
The other noted result was that the increased metabolic rates did not come at the expense of increased appetite and food consumption.
Study 2 Results
The Department of Pharmacology and Physiology, Saint Louis University conducted research into the impact of SARMs, specifically SR9009, on both sleep and metabolic rates. As the regulation of sleep and metabolism are triggered by the same receptors (REV-ERBα and REV-ERBβ), a close observation of the two was required.
The main aim was to identify the suitability of the drug to treat sleep disorders, including narcolepsy and insomnia. Both of these are tied to a protein called Orexin, and when this is out of balance, severe sleep disorders can be encountered.
The outcome of the study was that a significant positive effects on metabolic rates were observed. The reason for this is that Orexin is not just associated to regulating sleep cycles.
The overlapping pathway on metabolic and sleep processes was specifically highlighted as an area for further study and exploration. With the selective nature of the drugs, no negative side effects were noted.
Study 3 Results
The final study we want to focus on was conducted by University of Tennessee Health Science Center in 2017. The study was designed to show a full developmental history of SARMs from their initial proof of concept to the clinical test stages.
Their research highlighted the main positive benefits which included cancer treatment, muscle wasting and osteoporosis. With various levels of success the results have been very promising in many different fields of medicine.
The selective nature is the main benefit, but along with the treatments targeted, multiple studies were identified that showed positive side effects on metabolic rates. This has led to further investigations and developments of drugs specifically designed to treat metabolic illnesses.
One potential area of further study is using SARMs for the treatment of obesity by boosting metabolism rates, even when the body is in a resting phase in particular with GW-501516.
While numerous studies have highlighted the benefit of metabolic rates increasing, further studies particularly targeting this effect are needed. This will require the selection of target groups that can help identify the exact physiological process as well as any other potential side effects.
With huge potential for the medical industry SARMs are in some advanced stages of trial. But full approval is still quite a hurdle, due to regulatory approval processes which are more stringent on completely new types of drugs.